A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

This is a Phase 1 dose escalation study to assess the safety and tolerability of
subcutaneously administered SDX-7320 in patients with advanced refractory or late-stage
solid tumors.

Once the MTD has been determined a total of 12 patients will be treated at this dose level,
to further characterize treatment emergent adverse events (TEAEs).

Inclusion Criteria:

- Patients have at least one site of radiographically measurable disease.

- Eastern Cooperative Oncology Group (ECOG) status ≤1.

- Adequate renal and liver functions.

- Life expectancy ≥3 months.

Exclusion Criteria:

- Patients that have undergone organ transplant surgery.

- The patient has a known history of Hepatitis A, B, or C and is on active anti-viral
therapy.

- History of gastric bypass surgery or banding procedure.

- Uncontrolled or refractory hypertension: systolic >180 or diastolic >110, or
hypotension: systolic <90 or diastolic <50 despite medical treatment.

- Participation in any other trial of an investigational agent within 30 days prior to
enrollment.

- The resting 12-lead electrocardiogram obtained during screening shows QTc (Bazett's
correction) ≥470 ms or has a congenital prolonged QT syndrome.